Terns Pharma rises as obesity drug cuts weight by 4.9% in early study

Terns Pharmaceuticals

09/09/2024 12:55

** Shares of drug developer Terns Pharmaceuticals  TERN.O 
rise 36.11% to $10.63 premarket  
    ** Co says its experimental oral obesity drug showed average
weight loss of 4.9% in comparison with placebo in an early-stage
study
    ** Drug TERN-601, dosed once-daily, was tested in healthy
obese or overweight adults in a two-part early-stage trial 
    ** Co plans to initiate mid-stage trial in 2025
    ** Up to previous close, stock up 20.3% YTD

 (Reporting by Sneha S K and Sriparna Roy in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))